Not Yet RecruitingEarly Phase 1

A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine

100 participantsStarted 2026-08-13

Plain-language summary

Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 50 years old; * The participant can provide personal informed consent and sign the informed consent form; * temperature ≤ 37.0℃ on the day of administration; * capable of complying with the requirements of the clinical trial protocol to complete the trial. Exclusion Criteria: * Subjects with immunodeficiency or immunosuppression caused by underlying diseases or treatments, including primary/acquired immunodeficiency (e.g., AIDS and other virus-induced immunodeficiency), hematologic malignancies (leukemia, lymphoma or other bone marrow/lymphoid neoplasms), ongoing immunosuppressive therapy, or radiotherapy/chemotherapy for malignancies. * Subjects with a history of allergic reaction to any component of the investigational product. * Subjects with acute infection or acute exacerbation of chronic infection (vaccination should be deferred). * Women of non-postmenopausal status with positive pregnancy test, pregnant or lactating women, or those planning pregnancy within 6 months. * Subjects with prior history of herpes zoster. * Subjects with prior receipt of varicella or herpes zoster vaccine. * Receipt of live-attenuated vaccines within 14 days, or subunit/inactivated vaccines within 7 days prior to study vaccination. * Receipt of whole-blood, plasma or immunoglobulin within 5 months before, or within 3 weeks after study vaccination. * Receipt of investigational drugs from other clinical trials within 1 month before study vaccination, current parti…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

immunogenicity

Timeframe: 30 days after administration

Trial details

NCT IDNCT07753265

SponsorChangchun BCHT Biotechnology Co.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-09-20

Contact for this trial

Chen Xin

0431-87078295 chenxin@bchtpharm.com

View on ClinicalTrials.gov More Herpse Zoster trials

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.